<!doctype html><html lang=es-es dir=ltr data-wc-theme-default=system><head><meta charset=utf-8><meta name=viewport content="width=device-width,initial-scale=1"><meta http-equiv=X-UA-Compatible content="IE=edge"><meta name=generator content="Hugo Blox Builder 0.3.1"><meta name=author content="Maicel"><meta name=description content="üéß Escucha el podcast de esta publicaci√≥n Introducci√≥n: Fundamentos de evidencia confirmatoria Los ensayos cl√≠nicos controlados, aleatorizados y enmascarados (ECAs) constituyen el marco metodol√≥gico m√°s robusto para evaluar la eficacia y seguridad de nuevas intervenciones terap√©uticas. Son considerados el &ldquo;est√°ndar de oro&rdquo; en investigaci√≥n cl√≠nica por agencias como ICH, EMA y FDA, ya que proporcionan el mayor control contra el sesgo y la mayor solidez en inferencia causal.
"><link rel=alternate hreflang=es-es href=https://maicel.netlify.app/posts/atajos/><link rel=stylesheet href=/css/themes/sky.min.css><link href=/dist/wc.min.40d365a5c94bd94585e708f7c92e5782e00a8d8eefc348f5d2f21a80bb7783c8.css rel=stylesheet><script>window.hbb={defaultTheme:document.documentElement.dataset.wcThemeDefault,setDarkTheme:()=>{document.documentElement.classList.add("dark"),document.documentElement.style.colorScheme="dark"},setLightTheme:()=>{document.documentElement.classList.remove("dark"),document.documentElement.style.colorScheme="light"}},console.debug(`Default Hugo Blox Builder theme is ${window.hbb.defaultTheme}`),"wc-color-theme"in localStorage?localStorage.getItem("wc-color-theme")==="dark"?window.hbb.setDarkTheme():window.hbb.setLightTheme():(window.hbb.defaultTheme==="dark"?window.hbb.setDarkTheme():window.hbb.setLightTheme(),window.hbb.defaultTheme==="system"&&(window.matchMedia("(prefers-color-scheme: dark)").matches?window.hbb.setDarkTheme():window.hbb.setLightTheme()))</script><script>document.addEventListener("DOMContentLoaded",function(){let e=document.querySelectorAll("li input[type='checkbox'][disabled]");e.forEach(e=>{e.parentElement.parentElement.classList.add("task-list")});const t=document.querySelectorAll(".task-list li");t.forEach(e=>{let t=Array.from(e.childNodes).filter(e=>e.nodeType===3&&e.textContent.trim().length>1);if(t.length>0){const n=document.createElement("label");t[0].after(n),n.appendChild(e.querySelector("input[type='checkbox']")),n.appendChild(t[0])}})})</script><script async src="https://www.googletagmanager.com/gtag/js?id=G-VN0YPKYGX4"></script><script>window.dataLayer=window.dataLayer||[];function gtag(){dataLayer.push(arguments)}function trackOutboundLink(e,t){gtag("event","click",{event_category:"outbound",event_label:e,transport_type:"beacon",event_callback:function(){t!=="_blank"&&(document.location=e)}}),console.debug("Outbound link clicked: "+e)}function onClickCallback(e){if(e.target.tagName!=="A"||e.target.host===window.location.host)return;trackOutboundLink(e.target,e.target.getAttribute("target"))}gtag("js",new Date),gtag("config","G-VN0YPKYGX4",{}),gtag("set",{cookie_flags:"SameSite=None;Secure"}),document.addEventListener("click",onClickCallback,!1)</script><link rel=icon type=image/png href=/media/icon_hu_b45ae4411cf43192.png><link rel=apple-touch-icon type=image/png href=/media/icon_hu_1f7e870b5f23a0ce.png><link rel=canonical href=https://maicel.netlify.app/posts/atajos/><meta property="twitter:card" content="summary_large_image"><meta property="twitter:site" content="@GetResearchDev"><meta property="twitter:creator" content="@GetResearchDev"><meta property="og:site_name" content="Bioestad√≠stica edu"><meta property="og:url" content="https://maicel.netlify.app/posts/atajos/"><meta property="og:title" content="Dise√±os Alternativos a Ensayos Cl√≠nicos Controlados Aleatorizados: Contextos de Aplicaci√≥n y Riesgos Regulatorios | Bioestad√≠stica edu"><meta property="og:description" content="üéß Escucha el podcast de esta publicaci√≥n








  









  


Introducci√≥n: Fundamentos de evidencia confirmatoria
Los ensayos cl√≠nicos controlados, aleatorizados y enmascarados (ECAs) constituyen el marco metodol√≥gico m√°s robusto para evaluar la eficacia y seguridad de nuevas intervenciones terap√©uticas. Son considerados el &ldquo;est√°ndar de oro&rdquo; en investigaci√≥n cl√≠nica por agencias como ICH, EMA y FDA, ya que proporcionan el mayor control contra el sesgo y la mayor solidez en inferencia causal."><meta property="og:image" content="https://maicel.netlify.app/posts/atajos/featured.png"><meta property="twitter:image" content="https://maicel.netlify.app/posts/atajos/featured.png"><meta property="og:locale" content="es-es"><meta property="article:published_time" content="2025-08-07T00:00:00+00:00"><meta property="article:modified_time" content="2025-08-07T00:00:00+00:00"><title>Dise√±os Alternativos a Ensayos Cl√≠nicos Controlados Aleatorizados: Contextos de Aplicaci√≥n y Riesgos Regulatorios | Bioestad√≠stica edu</title><style>@font-face{font-family:inter var;font-style:normal;font-weight:100 900;font-display:swap;src:url(/dist/font/Inter.var.woff2)format(woff2)}</style><link type=text/css rel=stylesheet href=/dist/pagefind/pagefind-ui.be766eb419317a14ec769d216e9779bfe8f3737c80e780f4ba0dafb57a41a482.css integrity="sha256-vnZutBkxehTsdp0hbpd5v+jzc3yA54D0ug2vtXpBpII="><script src=/dist/pagefind/pagefind-ui.87693d7c6f2b3b347ce359d0ede762c033419f0a32b22ce508c335a81d841f1b.js integrity="sha256-h2k9fG8rOzR841nQ7ediwDNBnwoysizlCMM1qB2EHxs="></script><script>window.hbb.pagefind={baseUrl:"/"}</script><style>html.dark{--pagefind-ui-primary:#eeeeee;--pagefind-ui-text:#eeeeee;--pagefind-ui-background:#152028;--pagefind-ui-border:#152028;--pagefind-ui-tag:#152028}</style><script>window.addEventListener("DOMContentLoaded",e=>{new PagefindUI({element:"#search",showSubResults:!0,baseUrl:window.hbb.pagefind.baseUrl,bundlePath:window.hbb.pagefind.baseUrl+"pagefind/"})}),document.addEventListener("DOMContentLoaded",()=>{let e=document.getElementById("search"),t=document.getElementById("search_toggle");t&&t.addEventListener("click",()=>{if(e.classList.toggle("hidden"),e.querySelector("input").value="",e.querySelector("input").focus(),!e.classList.contains("hidden")){let t=document.querySelector(".pagefind-ui__search-clear");t&&!t.hasAttribute("listenerOnClick")&&(t.setAttribute("listenerOnClick","true"),t.addEventListener("click",()=>{e.classList.toggle("hidden")}))}})})</script><script defer src=/js/hugo-blox-es.min.e6965f872775fcb889e784756e346e58af6799db6f12e6c21a12272f7d3b1c1e.js integrity="sha256-5pZfhyd1/LiJ54R1bjRuWK9nmdtvEubCGhInL307HB4="></script></head><body class="dark:bg-hb-dark dark:text-white page-wrapper" id=top><div id=page-bg></div><div class="page-header sticky top-0 z-30"><header id=site-header class=header><nav class="navbar px-3 flex justify-left"><div class="order-0 h-100"><a class=navbar-brand href=/ title="Bioestad√≠stica edu">Maicel Monzon</a></div><input id=nav-toggle type=checkbox class=hidden>
<label for=nav-toggle class="order-3 cursor-pointer flex items-center lg:hidden text-dark dark:text-white lg:order-1"><svg id="show-button" class="h-6 fill-current block" viewBox="0 0 20 20"><title>Open Menu</title><path d="M0 3h20v2H0V3zm0 6h20v2H0V9zm0 6h20v2H0V0z"/></svg><svg id="hide-button" class="h-6 fill-current hidden" viewBox="0 0 20 20"><title>Close Menu</title><polygon points="11 9 22 9 22 11 11 11 11 22 9 22 9 11 -2 11 -2 9 9 9 9 -2 11 -2" transform="rotate(45 10 10)"/></svg></label><ul id=nav-menu class="navbar-nav order-3 hidden lg:flex w-full pb-6 lg:order-1 lg:w-auto lg:space-x-2 lg:pb-0 xl:space-x-8 justify-left"><li class=nav-item><a class=nav-link href=/>Biograf√≠a</a></li><li class=nav-item><a class=nav-link href=/#papers>Publicaciones</a></li><li class=nav-item><a class=nav-link href=/#talks>Conferencias</a></li><li class=nav-item><a class=nav-link href=/experience/>Experiencia</a></li><li class=nav-item><a class=nav-link href=/projects/>Proyectos</a></li><li class=nav-item><a class=nav-link href=/teaching/>Docencia</a></li><li class="nav-item nav-dropdown group relative"><span class="nav-link
inline-flex items-center">Blog<svg class="h-4 w-4 fill-current inline-block" viewBox="0 0 20 20"><path d="M9.293 12.95l.707.707L15.657 8l-1.414-1.414L10 10.828 5.757 6.586 4.343 8z"/></svg></span><ul class="nav-dropdown-list lg:group-hover:visible lg:group-hover:opacity-100"><li class=nav-dropdown-item><a class=nav-dropdown-link href=/posts/>Ver Todos los Art√≠culos</a></li><li class=nav-dropdown-item><a class=nav-dropdown-link href=/categories/estadistica-en-salud/>Estad√≠stica en Salud</a></li><li class=nav-dropdown-item><a class=nav-dropdown-link href=/categories/metodologia-de-investigacion/>Metodolog√≠a de Investigaci√≥n</a></li><li class=nav-dropdown-item><a class=nav-dropdown-link href=/categories/evaluacion-regulatoria/>Evaluaci√≥n Regulatoria</a></li><li class=nav-dropdown-item><a class=nav-dropdown-link href=/categories/codigo-practico-en-r-o-python/>C√≥digo Pr√°ctico en R/Python</a></li><li class=nav-dropdown-item><a class=nav-dropdown-link href=/categories/reflexiones-criticas/>Reflexiones Cr√≠ticas</a></li></ul></li><li class=nav-item><a class=nav-link href=/subscribe/>Suscr√≠bete</a></li></ul><div class="order-1 ml-auto flex items-center md:order-2 lg:ml-0"><button aria-label=search class="text-black hover:text-primary inline-block px-3 text-xl dark:text-white" id=search_toggle><svg height="16" width="16" viewBox="0 0 512 512" fill="currentcolor"><path d="M416 208c0 45.9-14.9 88.3-40 122.7L502.6 457.4c12.5 12.5 12.5 32.8.0 45.3s-32.8 12.5-45.3.0L330.7 376c-34.4 25.2-76.8 40-122.7 40C93.1 416 0 322.9.0 208S93.1.0 208 0 416 93.1 416 208zM208 352a144 144 0 100-288 144 144 0 100 288z"/></svg></button><div class="px-3 text-black hover:text-primary-700 dark:text-white dark:hover:text-primary-300
[&.active]:font-bold [&.active]:text-black/90 dark:[&.active]:text-white"><button class="theme-toggle mt-1" accesskey=t title=appearance><svg id="moon" width="24" height="18" viewBox="0 0 24 24" fill="none" stroke="currentcolor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="dark:hidden"><path d="M21 12.79A9 9 0 1111.21 3 7 7 0 0021 12.79z"/></svg><svg id="sun" width="24" height="18" viewBox="0 0 24 24" fill="none" stroke="currentcolor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="dark:block [&:not(dark)]:hidden"><circle cx="12" cy="12" r="5"/><line x1="12" y1="1" x2="12" y2="3"/><line x1="12" y1="21" x2="12" y2="23"/><line x1="4.22" y1="4.22" x2="5.64" y2="5.64"/><line x1="18.36" y1="18.36" x2="19.78" y2="19.78"/><line x1="1" y1="12" x2="3" y2="12"/><line x1="21" y1="12" x2="23" y2="12"/><line x1="4.22" y1="19.78" x2="5.64" y2="18.36"/><line x1="18.36" y1="5.64" x2="19.78" y2="4.22"/></svg></button></div></div></nav></header><div id=search class="hidden p-3"></div></div><div class="page-body my-10"><div class="mx-auto flex max-w-screen-xl"><aside class="hb-sidebar-container max-lg:[transform:translate3d(0,-100%,0)] lg:hidden xl:block"><div class="px-4 pt-4 lg:hidden"></div><div class="hb-scrollbar lg:h-[calc(100vh-var(--navbar-height))]"><ul class="flex flex-col gap-1 lg:hidden"><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/subscribe/>Suscr√≠bete a Nuestro Contenido</a></li><li class=open><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/posts/>Blog
<span data-hb-sidebar-toggle><svg fill="none" viewBox="0 0 24 24" stroke="currentcolor" class="h-[18px] min-w-[18px] rounded-sm p-0.5 hover:bg-gray-800/5 dark:hover:bg-gray-100/5"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 5l7 7-7 7" class="origin-center transition-transform rtl:-rotate-180"/></svg></span></a><div class="ltr:pr-0 overflow-hidden"><ul class=hb-sidebar-list><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/posts/imryd-redaccion-inversa/>¬øEscribir ciencia o reescribir la realidad?</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/posts/2025-09-24-correlacionvscausalidad/>Las trampas de la correlaci√≥n disfrazada de causalidad</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/posts/2025-09-06-ia/>Una Inmersi√≥n Intuitiva en la Arquitectura de los LLMs</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/posts/2025-09-01-generalizacion/>Del Laboratorio al Mundo Real</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/posts/2025-09-01-m-s-all-del-rct-en-salud-p-blica-y-epidemiolog-a/>Desvelando la L√≥gica Matem√°tica Detr√°s de Causa y Efecto</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/posts/2025-08-10-significacion/>Significaci√≥n Estad√≠stica: ¬øCiencia o Pirotecnia?</a></li><li class="flex flex-col open"><a class="hb-sidebar-custom-link
sidebar-active-item bg-primary-100 font-semibold text-primary-800 dark:bg-primary-300 dark:text-primary-900" href=/posts/atajos/>Dise√±os Alternativos a Ensayos Cl√≠nicos Controlados Aleatorizados: Contextos de Aplicaci√≥n y Riesgos Regulatorios</a><ul class=hb-sidebar-mobile-toc><li><a href=#tabla-1-t%c3%a9rminos-clave-definici%c3%b3n-origen-normativo-y-funci%c3%b3n-regulatoria class=hb-docs-link>Tabla 1. T√©rminos clave: definici√≥n, origen normativo y funci√≥n regulatoria</a></li><li><a href=#tabla-2-garant%c3%adas-anti-sesgo-en-ecas class=hb-docs-link>Tabla 2. Garant√≠as anti-sesgo en ECAs</a></li><li><a href=#tabla-3-dise%c3%b1os-alternativos-justificaci%c3%b3n-limitaciones-y-requisitos-regulatorios class=hb-docs-link>Tabla 3. Dise√±os alternativos: justificaci√≥n, limitaciones y requisitos regulatorios</a></li><li><a href=# class=hb-docs-link></a></li><li><a href=#a-para-la-industria class=hb-docs-link>A. Para la industria</a></li><li><a href=#b-para-las-agencias-reguladoras class=hb-docs-link>B. Para las agencias reguladoras</a></li></ul></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/posts/2025-02-11-eda/>An√°lisis Exploratorio de Datos: Desentra√±ando la Verdad de tus Datos</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/posts/2025-02-08-como-entrenar-y-validar-un-modelo-de-machine-learnig/>C√≥mo entrenar y validar un modelo de predicci√≥n cl√≠nica</a></li></ul></div></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/project/>Projects
<span data-hb-sidebar-toggle><svg fill="none" viewBox="0 0 24 24" stroke="currentcolor" class="h-[18px] min-w-[18px] rounded-sm p-0.5 hover:bg-gray-800/5 dark:hover:bg-gray-100/5"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 5l7 7-7 7" class="origin-center transition-transform rtl:-rotate-180"/></svg></span></a><div class="ltr:pr-0 overflow-hidden"><ul class=hb-sidebar-list><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/project/simed-simulacion-medica-en-linea/>SIMED: Simulaci√≥n M√©dica en L√≠nea para el Aprendizaje del Proceso de Atenci√≥n</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/project/plate-to-policy-real-time-ai-driven-insights-for-smarter-food-fortification/>MacroScope AI: Real-Time Nutrition Insights for Smarter Food Systems</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/project/covidcencecapk/>CovidCencecAPK</a></li></ul></div></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/teaching/>Teaching
<span data-hb-sidebar-toggle><svg fill="none" viewBox="0 0 24 24" stroke="currentcolor" class="h-[18px] min-w-[18px] rounded-sm p-0.5 hover:bg-gray-800/5 dark:hover:bg-gray-100/5"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 5l7 7-7 7" class="origin-center transition-transform rtl:-rotate-180"/></svg></span></a><div class="ltr:pr-0 overflow-hidden"><ul class=hb-sidebar-list><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/teaching/introducci-n-a-los-dise-os-explicativos-experimentales/>Introducci√≥n a los dise√±os explicativos experimentales</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/teaching/conferencia-introducci-n-al-an-lisis-estad-stico-en-ensayos-cl-nicos/>Conferencia de Introducci√≥n al an√°lisis estad√≠stico en ensayos cl√≠nicos</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/teaching/2025-03-05-tutorial-an-lisis-de-fortificaci-n-de-alimentos-con-hces-y-r/>Tutorial: An√°lisis de Fortificaci√≥n de Alimentos con HCES y R</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/teaching/r/>Curso de An√°lisis de datos en fortificaci√≥n de alimentos a gran escala con R. Una Introducci√≥n Pr√°ctica</a></li></ul></div></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/event/>Recent & Upcoming Talks
<span data-hb-sidebar-toggle><svg fill="none" viewBox="0 0 24 24" stroke="currentcolor" class="h-[18px] min-w-[18px] rounded-sm p-0.5 hover:bg-gray-800/5 dark:hover:bg-gray-100/5"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 5l7 7-7 7" class="origin-center transition-transform rtl:-rotate-180"/></svg></span></a><div class="ltr:pr-0 overflow-hidden"><ul class=hb-sidebar-list><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/event/example/>üëã Curso de An√°lisis de Datos en Fortificaci√≥n de Alimentos con R. Una Introducci√≥n Pr√°ctica</a></li></ul></div></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href><span data-hb-sidebar-toggle><svg fill="none" viewBox="0 0 24 24" stroke="currentcolor" class="h-[18px] min-w-[18px] rounded-sm p-0.5 hover:bg-gray-800/5 dark:hover:bg-gray-100/5"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 5l7 7-7 7" class="origin-center transition-transform rtl:-rotate-180"/></svg></span></a><div class="ltr:pr-0 overflow-hidden"><ul class=hb-sidebar-list><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href>Maicel</a></li></ul></div></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/projects/>Projects</a></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/experience/>Experience</a></li><li><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/publication/>Publications
<span data-hb-sidebar-toggle><svg fill="none" viewBox="0 0 24 24" stroke="currentcolor" class="h-[18px] min-w-[18px] rounded-sm p-0.5 hover:bg-gray-800/5 dark:hover:bg-gray-100/5"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M9 5l7 7-7 7" class="origin-center transition-transform rtl:-rotate-180"/></svg></span></a><div class="ltr:pr-0 overflow-hidden"><ul class=hb-sidebar-list><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/publication/journal-article/>Estado en la investigaci√≥n sobre modelos de predicci√≥n de la severidad en confirmados de la Covid-19.</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/publication/preprint/>Identificaci√≥n de pacientes de bajo riesgo de severidad en confirmados de la COVID-19. Cuba. A√±os 2020-2021</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/publication/2025-09-23-modelo-sir-para-epidemias-persistencia-en-el-tiempo-y-nuevos-retos-en-la-era-de-la-inform-tica-y-las-pandemias/>Modelo SIR para epidemias: Persistencia en el tiempo y nuevos retos en la era de la Inform√°tica y las pandemias.</a></li><li class="flex flex-col"><a class="hb-sidebar-custom-link
text-gray-500 hover:bg-gray-100 hover:text-gray-900 dark:text-gray-300 dark:hover:bg-primary-800 dark:hover:text-gray-50" href=/publication/2025-09-23-plagio-en-art-culos-de-investigaci-n-en-revistas-biom-dicas-cubanas-2016/>Plagio en art√≠culos de investigaci√≥n en revistas biom√©dicas cubanas. 2016</a></li></ul></div></li></ul><div class="max-xl:hidden h-0 w-64 shrink-0"></div></div></aside><nav class="hb-toc order-last hidden w-64 shrink-0 xl:block print:hidden px-4" aria-label="table of contents"><div class="hb-scrollbar text-sm [hyphens:auto] sticky top-16 overflow-y-auto pr-4 pt-6 max-h-[calc(100vh-var(--navbar-height)-env(safe-area-inset-bottom))] -mr-4 rtl:-ml-4"><p class="mb-4 font-semibold tracking-tight">En esta p√°gina</p><ul><li class="my-2 scroll-my-6 scroll-py-6"><a class="font-semibold inline-block text-gray-500 hover:text-gray-900 dark:text-gray-400 dark:hover:text-gray-300 w-full break-words" href=#tabla-1-t%c3%a9rminos-clave-definici%c3%b3n-origen-normativo-y-funci%c3%b3n-regulatoria>Tabla 1. T√©rminos clave: definici√≥n, origen normativo y funci√≥n regulatoria</a></li></ul><ul><li class="my-2 scroll-my-6 scroll-py-6"><a class="font-semibold inline-block text-gray-500 hover:text-gray-900 dark:text-gray-400 dark:hover:text-gray-300 w-full break-words" href=#tabla-2-garant%c3%adas-anti-sesgo-en-ecas>Tabla 2. Garant√≠as anti-sesgo en ECAs</a></li></ul><ul></ul><ul><li class="my-2 scroll-my-6 scroll-py-6"><a class="font-semibold inline-block text-gray-500 hover:text-gray-900 dark:text-gray-400 dark:hover:text-gray-300 w-full break-words" href=#tabla-3-dise%c3%b1os-alternativos-justificaci%c3%b3n-limitaciones-y-requisitos-regulatorios>Tabla 3. Dise√±os alternativos: justificaci√≥n, limitaciones y requisitos regulatorios</a></li></ul><ul><li class="my-2 scroll-my-6 scroll-py-6"><a class="pl-4 rtl:pr-4 inline-block text-gray-500 hover:text-gray-900 dark:text-gray-400 dark:hover:text-gray-300 w-full break-words" href=#riesgos-identificados>Riesgos identificados:</a></li></ul><ul><li class="my-2 scroll-my-6 scroll-py-6"><a class="font-semibold inline-block text-gray-500 hover:text-gray-900 dark:text-gray-400 dark:hover:text-gray-300 w-full break-words" href=#a-para-la-industria>A. Para la industria</a></li><li class="my-2 scroll-my-6 scroll-py-6"><a class="font-semibold inline-block text-gray-500 hover:text-gray-900 dark:text-gray-400 dark:hover:text-gray-300 w-full break-words" href=#b-para-las-agencias-reguladoras>B. Para las agencias reguladoras</a></li></ul><ul></ul><ul></ul>
    
    
  </div></nav><article class="w-full break-words flex min-h-[calc(100vh-var(--navbar-height))] min-w-0 justify-center pb-8 pr-[calc(env(safe-area-inset-right)-1.5rem)]"><main class="w-full min-w-0 max-w-6xl px-6 pt-4 md:px-12"><h1 class="mt-2 text-4xl font-bold tracking-tight text-slate-900 dark:text-slate-100">Dise√±os Alternativos a Ensayos Cl√≠nicos Controlados Aleatorizados: Contextos de Aplicaci√≥n y Riesgos Regulatorios</h1><div class="mt-4 mb-16"><div class="text-gray-500 dark:text-gray-300 text-sm flex items-center flex-wrap gap-y-2"><span class=mr-1>ago. 7, 2025</span><span class=mx-1>¬∑</span>
<span class=mx-1>¬∑</span>
<span class=mx-1>5 min de lectura</span></div><div class=mt-3></div></div><div class="article-header article-container featured-image-wrapper mt-4 mb-16" style=max-width:720px;max-height:720px><div style=position:relative><img src=/posts/atajos/featured_hu_e6a2419f4e56d8da.webp width=720 height=720 alt class=featured-image></div></div><div class="prose prose-slate lg:prose-xl dark:prose-invert"><p>üéß <strong>Escucha el podcast de esta publicaci√≥n</strong>
<audio controls><source src=/mp3/atajos.mp3 type=audio/mpeg></audio></p><h1 id=introducci√≥n-fundamentos-de-evidencia-confirmatoria>Introducci√≥n: Fundamentos de evidencia confirmatoria</h1><p>Los ensayos cl√≠nicos controlados, aleatorizados y enmascarados (ECAs) constituyen el marco metodol√≥gico m√°s robusto para evaluar la <strong>eficacia y seguridad</strong> de nuevas intervenciones terap√©uticas. Son considerados el &ldquo;est√°ndar de oro&rdquo; en investigaci√≥n cl√≠nica por agencias como <strong>ICH, EMA y FDA</strong>, ya que proporcionan el mayor control contra el sesgo y la mayor solidez en inferencia causal.</p><p>En este marco, los <strong>ensayos confirmatorios</strong> son aquellos dise√±ados expl√≠citamente para confirmar hip√≥tesis cl√≠nicas relevantes, con base en an√°lisis predefinidos y control adecuado de errores. Cuando estos estudios sustentan una solicitud de comercializaci√≥n, adquieren la condici√≥n de <strong>ensayos pivotal</strong> (terminolog√≠a empleada por FDA y EMA).</p><p>En principio, se recomienda la presentaci√≥n de <strong>dos ensayos confirmatorios independientes</strong>. Sin embargo, <strong>tanto EMA como FDA</strong> contemplan aprobaciones basadas en <strong>un √∫nico ensayo pivotal</strong>, siempre que est√© respaldado por <strong>evidencia complementaria rigurosa</strong>. La <strong>FDA</strong>, mediante el concepto de <strong>evidencia confirmatoria</strong> (FDA 2023), formaliza esta v√≠a alternativa. La <strong>EMA</strong>, aunque no utiliza esa denominaci√≥n, acepta enfoques equivalentes (meta-an√°lisis, controles hist√≥ricos validados, an√°lisis de consistencia interna).</p><h2 id=tabla-1-t√©rminos-clave-definici√≥n-origen-normativo-y-funci√≥n-regulatoria>Tabla 1. T√©rminos clave: definici√≥n, origen normativo y funci√≥n regulatoria</h2><table><thead><tr><th><strong>T√©rmino</strong></th><th><strong>Fuente regulatoria</strong></th><th><strong>Definici√≥n t√©cnica</strong></th><th><strong>Funci√≥n regulatoria</strong></th></tr></thead><tbody><tr><td><strong>Ensayo cl√≠nico confirmatorio</strong></td><td>ICH E9</td><td>Estudio con hip√≥tesis expl√≠cita, an√°lisis planificado y dise√±o robusto para inferencia causal.</td><td>Fuente principal de evidencia en autorizaciones de comercializaci√≥n.</td></tr><tr><td><strong>Ensayo pivotal</strong></td><td>FDA, EMA</td><td>Estudio esencial para demostrar eficacia y seguridad en el expediente regulatorio.</td><td>Sustento central del dossier cl√≠nico.</td></tr><tr><td><strong>Evidencia confirmatoria</strong></td><td>FDA (2023)</td><td>Datos adicionales (cl√≠nicos/no cl√≠nicos) que refuerzan un ensayo pivotal √∫nico.</td><td>Permite cumplir el est√°ndar de &ldquo;evidencia sustancial&rdquo; con un solo ECA.</td></tr><tr><td><strong>Evidencia sustancial</strong></td><td>FDA (21 CFR 314.126)</td><td>Est√°ndar legal que puede cumplirse mediante 2 ECAs o, cuando est√© justificado, 1 ECA + confirmaci√≥n.</td><td>Requisito para la aprobaci√≥n de nuevos medicamentos en EE.UU.</td></tr><tr><td><strong>Evidencia complementaria</strong></td><td>ICH E9; EMA, FDA</td><td>Estudios no pivotal que aportan consistencia (ej. subgrupos, dosis, seguridad, datos externos).</td><td>Reforzar la plausibilidad de los hallazgos principales.</td></tr></tbody></table><hr><h1 id=estructura-metodol√≥gica-de-los-ecas-y-su-anclaje-normativo>Estructura metodol√≥gica de los ECAs y su anclaje normativo</h1><p>Los ECAs incorporan tres garant√≠as fundamentales: <strong>aleatorizaci√≥n</strong>, <strong>grupo control</strong> y <strong>cegamiento</strong>. Estos componentes son esenciales para maximizar la validez interna y minimizar fuentes de sesgo sistem√°tico.</p><h2 id=tabla-2-garant√≠as-anti-sesgo-en-ecas>Tabla 2. Garant√≠as anti-sesgo en ECAs</h2><table><thead><tr><th><strong>Componente metodol√≥gico</strong></th><th><strong>Funci√≥n espec√≠fica</strong></th><th><strong>C√≥mo reduce el sesgo</strong></th><th><strong>Referencia normativa ICH</strong></th></tr></thead><tbody><tr><td><strong>Aleatorizaci√≥n</strong></td><td>Asignaci√≥n no predecible de tratamientos</td><td>Mitiga el sesgo de selecci√≥n; equilibra factores conocidos/desconocidos</td><td>ICH E9 Secci√≥n 2.2.3</td></tr><tr><td><strong>Grupo control</strong></td><td>Comparaci√≥n con placebo o tratamiento est√°ndar</td><td>Permite contrafactual v√°lido e inferencia causal robusta</td><td>ICH E10; ICH E8(R1)</td></tr><tr><td><strong>Cegamiento (blinding)</strong></td><td>Ocultamiento de asignaci√≥n a participantes e investigadores</td><td>Previene sesgo de evaluaci√≥n, expectativa y cointervenci√≥n</td><td>ICH E9 Secci√≥n 2.2.4</td></tr></tbody></table><hr><h1 id=contextos-que-permiten-prescindir-de-ecas>Contextos que permiten prescindir de ECAs</h1><p>La omisi√≥n de ECAs solo es aceptable en contextos claramente delimitados por justificaciones √©ticas, cient√≠ficas o log√≠sticas:</p><ol><li><strong>Enfermedades raras o ultrarraras</strong>, con poblaciones muy limitadas.</li><li><strong>Situaciones de emergencia sanitaria</strong>, con necesidades cl√≠nicas urgentes.</li><li>Cuando la <strong>aleatorizaci√≥n o el cegamiento son √©ticamente problem√°ticos</strong>.</li><li>Cuando existen <strong>datos hist√≥ricos o reales bien estructurados y validados</strong>.</li></ol><p>La aceptaci√≥n de estos dise√±os como base regulatoria <strong>requiere validaci√≥n metodol√≥gica espec√≠fica y evaluaci√≥n caso por caso</strong>, seg√∫n gu√≠as EMA y FDA.</p><hr><h1 id=dise√±os-alternativos-m√°s-empleados-y-criterios-de-validaci√≥n>Dise√±os alternativos m√°s empleados y criterios de validaci√≥n</h1><h2 id=tabla-3-dise√±os-alternativos-justificaci√≥n-limitaciones-y-requisitos-regulatorios>Tabla 3. Dise√±os alternativos: justificaci√≥n, limitaciones y requisitos regulatorios</h2><table><thead><tr><th><strong>Dise√±o alternativo</strong></th><th><strong>Justificaci√≥n de uso</strong></th><th><strong>Limitaciones cr√≠ticas</strong></th><th><strong>Requisitos de validaci√≥n</strong></th></tr></thead><tbody><tr><td><strong>Single-Arm Trials (SAT)</strong></td><td>Enfermedades raras; oncolog√≠a sin comparador disponible</td><td>Ausencia de grupo control; alta vulnerabilidad a sesgo de selecci√≥n</td><td>Control externo robusto; endpoints validados; an√°lisis de consistencia</td></tr><tr><td><strong>Controles externos/sint√©ticos</strong></td><td>Cohortes hist√≥ricas o datos de mundo real</td><td>Riesgo de confusi√≥n residual y sesgo de canalizaci√≥n</td><td>Propensity score matching; alineaci√≥n temporal; CHMP/4366/2020 (EMA)</td></tr><tr><td><strong>Dise√±os adaptativos</strong></td><td>Eficiencia en reclutamiento; ajustes preplanificados</td><td>Riesgo de error tipo I si no se prespecifican adecuadamente</td><td>Control de multiplicidad; simulaci√≥n previa; ICH E9(R1)</td></tr><tr><td><strong>Real-World Evidence (RWE)</strong></td><td>Acceso a datos de rutina cl√≠nica; seguimiento largo; baja carga √©tica</td><td>Falta de aleatorizaci√≥n; sesgo de confusi√≥n no medido</td><td>PROACE principles (FDA 2023); data provenance; calidad del DMR; plan de an√°lisis riguroso</td></tr></tbody></table><hr><h1 id=riesgos-del-uso-estrat√©gico-de-dise√±os-no-confirmatorios>Riesgos del uso estrat√©gico de dise√±os no confirmatorios</h1><p>Aunque v√°lidos en contextos excepcionales, el uso frecuente y estrat√©gico de estos dise√±os plantea <strong>serios desaf√≠os regulatorios</strong>, especialmente si se recurre a ellos como v√≠a para <strong>prescindir de ECAs sin justificaci√≥n metodol√≥gica s√≥lida</strong>.</p><h3 id=riesgos-identificados>Riesgos identificados:</h3><ul><li>Aprobaciones basadas en <strong>evidencia d√©bil o no reproducible</strong>.</li><li>Incremento del <strong>sesgo sistem√°tico</strong> en resultados de eficacia.</li><li>Exposici√≥n de pacientes a intervenciones <strong>no validadas rigurosamente</strong>.</li><li><strong>Deslegitimaci√≥n del proceso regulatorio</strong> ante la comunidad cient√≠fica y la sociedad.</li></ul><hr><h1 id=recomendaciones-regulatorias>Recomendaciones regulatorias</h1><h2 id=a-para-la-industria>A. Para la industria</h2><ul><li>Presentar <strong>justificaci√≥n exhaustiva</strong> cuando no se utilicen ECAs.</li><li>Cumplir con requisitos metodol√≥gicos espec√≠ficos seg√∫n tipo de dise√±o alternativo.</li><li>Incluir an√°lisis de sensibilidad, consistencia y control de sesgo.</li></ul><h2 id=b-para-las-agencias-reguladoras>B. Para las agencias reguladoras</h2><ul><li><strong>Reforzar gu√≠as espec√≠ficas</strong> (EMA, FDA) que regulen el uso de dise√±os alternativos.</li><li>Exigir <strong>registro p√∫blico</strong>, transparencia y acceso a protocolos completos.</li><li>Fortalecer <strong>capacidades internas</strong> en estad√≠stica avanzada y dise√±o de estudios no aleatorizados.</li><li>Establecer <strong>comit√©s independientes</strong> de evaluaci√≥n para salvaguardas √©ticas y cient√≠ficas.</li></ul><hr><h1 id=conclusi√≥n>Conclusi√≥n</h1><p>Los dise√±os alternativos no deben entenderse como sustitutos gen√©ricos del ECA, sino como herramientas <strong>v√°lidas solo bajo condiciones estrictamente justificadas y validadas</strong>. El regulador tiene la responsabilidad cient√≠fica y √©tica de exigir evidencia que no solo sea suficiente, sino tambi√©n s√≥lida, reproducible y libre de sesgos. La precisi√≥n metodol√≥gica y la claridad terminol√≥gica no son un lujo en este proceso: <strong>son el principio rector que protege la salud p√∫blica frente a la ambig√ºedad cient√≠fica</strong>.</p><hr><h1 id=bibliograf√≠a>Bibliograf√≠a</h1><ol><li>FDA. <em>Demonstrating Substantial Evidence of Effectiveness with One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence</em>. Draft Guidance. 2023.</li><li>EMA. <em>Reflection Paper on Single‚ÄëArm Trials as Pivotal Evidence</em>. EMA/CHMP/161300/2023.</li><li>FDA. <em>Real-World Evidence Framework</em>. 2023 Update.</li><li>EMA. <em>Use of Real‚ÄëWorld Evidence in Regulatory Decision-Making</em>. EMA/INS/GCP/455222/2024.</li><li>ICH. <em>E9: Statistical Principles for Clinical Trials</em>. 1998.</li><li>ICH. <em>E9(R1): Addendum on Estimands and Sensitivity Analysis in Clinical Trials</em>. 2020.</li><li>EMA. <em>Guideline on Adjustment for Baseline Covariates in Clinical Trials</em>. CHMP/EWP/2863/99.</li><li>FDA. <em>Real-World Evidence Program Annual Report 2025 (PUB-245)</em>.</li><li>Temple R, Ellenberg SS. <em>Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments</em>. <em>Ann Intern Med</em>. 2000;133(6):455‚Äì463.</li></ol></div><time class="mt-12 mb-8 block text-xs text-gray-500 ltr:text-right rtl:text-left dark:text-gray-400" datetime=2025-08-07T00:00:00.000Z><span>√öltima actualizaci√≥n el</span>
ago. 7, 2025</time><div class="container mx-auto prose prose-slate lg:prose-xl dark:prose-invert mt-5"><div class="max-w-prose print:hidden"><div class="flex justify-center"><a class="no-underline bg-primary-100 hover:bg-primary-300 text-primary-800 text-xs font-medium mr-2 px-2.5 py-0.5 lg:px-5 lg:py-2 rounded dark:bg-primary-900 dark:hover:bg-primary-700 dark:text-primary-300" href=/tags/atajos-disenos-ensayos-clinicos-y-riesgos-ich/>Atajos Dise√±os Ensayos Cl√≠nicos Y Riesgos ICH</a>
<a class="no-underline bg-primary-100 hover:bg-primary-300 text-primary-800 text-xs font-medium mr-2 px-2.5 py-0.5 lg:px-5 lg:py-2 rounded dark:bg-primary-900 dark:hover:bg-primary-700 dark:text-primary-300" href=/tags/errores-que-detienen-aprobaciones-ema-fda/>Errores Que Detienen Aprobaciones EMA FDA</a>
<a class="no-underline bg-primary-100 hover:bg-primary-300 text-primary-800 text-xs font-medium mr-2 px-2.5 py-0.5 lg:px-5 lg:py-2 rounded dark:bg-primary-900 dark:hover:bg-primary-700 dark:text-primary-300" href=/tags/critica-sesgos-en-ensayos-alternativos/>Cr√≠tica Sesgos en Ensayos Alternativos</a>
<a class="no-underline bg-primary-100 hover:bg-primary-300 text-primary-800 text-xs font-medium mr-2 px-2.5 py-0.5 lg:px-5 lg:py-2 rounded dark:bg-primary-900 dark:hover:bg-primary-700 dark:text-primary-300" href=/tags/guia-validacion-regulatoria-para-evaluadores/>Gu√≠a Validaci√≥n Regulatoria Para Evaluadores</a></div><section class="flex flex-row flex-wrap justify-center pt-4 text-xl"><a target=_blank rel=noopener class="m-1 rounded-md bg-neutral-300 p-1.5 text-neutral-700 hover:bg-primary-500 hover:text-neutral-300 dark:bg-neutral-700 dark:text-neutral-300 dark:hover:bg-primary-400 dark:hover:text-neutral-800" href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fmaicel.netlify.app%2Fposts%2Fatajos%2F&amp;text=Dise%C3%B1os+Alternativos+a+Ensayos+Cl%C3%ADnicos+Controlados+Aleatorizados%3A+Contextos+de+Aplicaci%C3%B3n+y+Riesgos+Regulatorios" title=X aria-label=X id=share-link-x><svg style="height:1em" viewBox="0 0 512 512"><path fill="currentcolor" d="M389.2 48h70.6L305.6 224.2 487 464H345L233.7 318.6 106.5 464H35.8L200.7 275.5 26.8 48H172.4L272.9 180.9 389.2 48zM364.4 421.8h39.1L151.1 88h-42L364.4 421.8z"/></svg>
</a><a target=_blank rel=noopener class="m-1 rounded-md bg-neutral-300 p-1.5 text-neutral-700 hover:bg-primary-500 hover:text-neutral-300 dark:bg-neutral-700 dark:text-neutral-300 dark:hover:bg-primary-400 dark:hover:text-neutral-800" href="https://www.facebook.com/sharer.php?u=https%3A%2F%2Fmaicel.netlify.app%2Fposts%2Fatajos%2F&amp;t=Dise%C3%B1os+Alternativos+a+Ensayos+Cl%C3%ADnicos+Controlados+Aleatorizados%3A+Contextos+de+Aplicaci%C3%B3n+y+Riesgos+Regulatorios" title=Facebook aria-label=Facebook id=share-link-facebook><svg style="height:1em" viewBox="0 0 24 24"><path fill="currentcolor" d="M22 12c0-5.52-4.48-10-10-10S2 6.48 2 12c0 4.84 3.44 8.87 8 9.8V15H8v-3h2V9.5C10 7.57 11.57 6 13.5 6H16v3h-2c-.55.0-1 .45-1 1v2h3v3h-3v6.95c5.05-.5 9-4.76 9-9.95z"/></svg>
</a><a target=_blank rel=noopener class="m-1 rounded-md bg-neutral-300 p-1.5 text-neutral-700 hover:bg-primary-500 hover:text-neutral-300 dark:bg-neutral-700 dark:text-neutral-300 dark:hover:bg-primary-400 dark:hover:text-neutral-800" href="mailto:?subject=Dise%C3%B1os%20Alternativos%20a%20Ensayos%20Cl%C3%ADnicos%20Controlados%20Aleatorizados%3A%20Contextos%20de%20Aplicaci%C3%B3n%20y%20Riesgos%20Regulatorios&amp;body=https%3A%2F%2Fmaicel.netlify.app%2Fposts%2Fatajos%2F" title=Email aria-label=Email id=share-link-email><svg style="height:1em" viewBox="0 0 24 24"><path fill="none" stroke="currentcolor" stroke-linecap="round" stroke-width="1.5" d="M16.5 12a4.5 4.5.0 11-9 0 4.5 4.5.0 019 0zm0 0c0 1.657 1.007 3 2.25 3S21 13.657 21 12a9 9 0 10-2.636 6.364M16.5 12V8.25"/></svg>
</a><a target=_blank rel=noopener class="m-1 rounded-md bg-neutral-300 p-1.5 text-neutral-700 hover:bg-primary-500 hover:text-neutral-300 dark:bg-neutral-700 dark:text-neutral-300 dark:hover:bg-primary-400 dark:hover:text-neutral-800" href="https://www.linkedin.com/shareArticle?url=https%3A%2F%2Fmaicel.netlify.app%2Fposts%2Fatajos%2F&amp;title=Dise%C3%B1os+Alternativos+a+Ensayos+Cl%C3%ADnicos+Controlados+Aleatorizados%3A+Contextos+de+Aplicaci%C3%B3n+y+Riesgos+Regulatorios" title=LinkedIn aria-label=LinkedIn id=share-link-linkedin><svg style="height:1em" height="1em" viewBox="0 0 448 512"><path fill="currentcolor" d="M416 32H31.9C14.3 32 0 46.5.0 64.3v383.4C0 465.5 14.3 480 31.9 480H416c17.6.0 32-14.5 32-32.3V64.3c0-17.8-14.4-32.3-32-32.3zM135.4 416H69V202.2h66.5V416zm-33.2-243c-21.3.0-38.5-17.3-38.5-38.5S80.9 96 102.2 96c21.2.0 38.5 17.3 38.5 38.5.0 21.3-17.2 38.5-38.5 38.5zm282.1 243h-66.4V312c0-24.8-.5-56.7-34.5-56.7-34.6.0-39.9 27-39.9 54.9V416h-66.4V202.2h63.7v29.2h.9c8.9-16.8 30.6-34.5 62.9-34.5 67.2.0 79.7 44.3 79.7 101.9V416z"/></svg>
</a><a target=_blank rel=noopener class="m-1 rounded-md bg-neutral-300 p-1.5 text-neutral-700 hover:bg-primary-500 hover:text-neutral-300 dark:bg-neutral-700 dark:text-neutral-300 dark:hover:bg-primary-400 dark:hover:text-neutral-800" href="whatsapp://send?text=Dise%C3%B1os+Alternativos+a+Ensayos+Cl%C3%ADnicos+Controlados+Aleatorizados%3A+Contextos+de+Aplicaci%C3%B3n+y+Riesgos+Regulatorios%20https%3A%2F%2Fmaicel.netlify.app%2Fposts%2Fatajos%2F" title=WhatsApp aria-label=WhatsApp id=share-link-whatsapp><svg style="height:1em" viewBox="0 0 256 256" fill="currentcolor"><path d="m187.58 144.84-32-16a8 8 0 00-8 .5l-14.69 9.8a40.55 40.55.0 01-16-16l9.8-14.69a8 8 0 00.5-8l-16-32A8 8 0 00104 64a40 40 0 00-40 40 88.1 88.1.0 0088 88 40 40 0 0040-40 8 8 0 00-4.42-7.16zM152 176a72.08 72.08.0 01-72-72 24 24 0 0119.29-23.54l11.48 23L101 118a8 8 0 00-.73 7.51 56.47 56.47.0 0030.15 30.15A8 8 0 00138 155l14.61-9.74 23 11.48A24 24 0 01152 176zM128 24A104 104 0 0036.18 176.88l-11.35 34.05a16 16 0 0020.24 20.24l34.05-11.35A104 104 0 10128 24zm0 192a87.87 87.87.0 01-44.06-11.81 8 8 0 00-6.54-.67L40 216l12.47-37.4a8 8 0 00-.66-6.54A88 88 0 11128 216z"/></svg></a></section><div class="pt-1 no-prose w-full"><hr class="border-dotted border-neutral-300 dark:border-neutral-600"><div class="flex flex-col md:flex-row flex-nowrap justify-between gap-5 pt-2"><div><a class="group flex no-underline" href=/posts/imryd-redaccion-inversa/><span class="mt-[-0.3rem] me-2 text-neutral-700 transition-transform group-hover:-translate-x-[2px] group-hover:text-primary-600 dark:text-neutral dark:group-hover:text-primary-400"><span class="ltr:inline rtl:hidden">&larr;</span></span>
<span class="flex flex-col"><span class="mt-[0.1rem] leading-6 group-hover:underline group-hover:decoration-primary-500">¬øEscribir ciencia o reescribir la realidad?</span>
<span class="mt-[0.1rem] text-xs text-neutral-500 dark:text-neutral-400">oct. 4, 2025</span></span></a></div><div></div></div></div><section id=comments><script src=https://giscus.app/client.js data-repo=maicel1978/mi-sitio-personal data-repo-id=R_kgDON3SOug data-category=Announcements data-category-id=DIC_kwDON3SOus4CrXLh data-mapping=pathname data-strict=0 data-reactions-enabled=1 data-emit-metadata=0 data-input-position=top data-theme=preferred_color_scheme data-lang=en data-loading=lazy crossorigin=anonymous async></script></section></div></div></main></article></div></div><div class=page-footer><footer class="container mx-auto flex flex-col justify-items-center text-sm leading-6 mt-24 mb-4 text-slate-700 dark:text-slate-200"><p class="powered-by text-center">¬© 2025 Me. This work is licensed under <a href=https://creativecommons.org/licenses/by-nc-nd/4.0 rel="noopener noreferrer" target=_blank>CC BY NC ND 4.0</a></p><p class="powered-by footer-license-icons"><a href=https://creativecommons.org/licenses/by-nc-nd/4.0 rel="noopener noreferrer" target=_blank aria-label="Creative Commons"><i class="fab fa-creative-commons fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-by fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-nc fa-2x" aria-hidden=true></i>
<i class="fab fa-creative-commons-nd fa-2x" aria-hidden=true></i></a></p><p class="powered-by text-center">Made with <a href="https://hugoblox.com/?utm_campaign=poweredby" target=_blank rel=noopener>Hugo Blox Builder</a>.</p></footer></div></body></html>